Depression research published in 2026 (page 23)

Prevalence of different parasomnias in the general Norwegian population, and their association with insomnia, anxiety, and depression. A cross-sectional web-panel survey

Frontiers in Sleep April 23, 2026 Erlend Haarr Drugli, Oskar Emil Lehmann, Ståle Pallesen et al.

Objective: To estimate the prevalence of various parasomnias in the general Norwegian adult population and explore their associations with insomnia, anxiety, and depression. Methods: A cross-sectional online survey was conducted in September 2024 among 1002 adults (50.7% male, mean age 50.3), drawn from a large population-based sample from a national web panel. Participants reported lifetime...

DOI: 10.3389/frsle.2026.1806980

Depression, anxiety, stress and mental well-being among Filipino sexual and gender minority university students: a cross-sectional study examining the mediating role of mindfulness.

Journal of Research in Nursing April 23, 2026 D. J. Berdida, Jhana Rai DC Panday, Annrhea Nicole S Domingo et al.

Background The mediating role of mindfulness among lesbian, gay, bisexual, transgender and queer (LGBTQ) university students from lower-middle-income countries like the Philippines remains unreported. Aims To examine the mediating role of mindfulness in the associations of depression, anxiety, stress and mental well-being among LGBTQ university students. Methods This cross-sectional...

DOI: 10.1177/17449871261438320 Full text

Ayahuasca Therapy: Possible Reduction of Suicidal Ideation in Treatment-Resistant Depression - A Systematic Review.

Journal of Psychoactive Drugs April 23, 2026 Brayan Jonas Mano-Sousa, Maria Clara Gama Fontes, Ana Clara Anacleto Gonçalves et al.

Suicide, particularly in treatment-resistant depression (TRD), remains a pressing global health issue, with over 700,000 annual deaths. Existing treatments often have limited efficacy and delayed onset, creating a need for rapid-acting interventions. Ayahuasca, a traditional Amazonian psychedelic, has shown potential for rapidly reducing suicidal ideation. Our systematic review evaluated the...

DOI: 10.1080/02791072.2026.2661580 Full text DMT Ayahuasca Neuroplasticity Psychedelic therapy +2

The moderating and mediating effects of mindful compassion with body-mind-spirit therapy using a blended approach of face-to-face with online for breast cancer patients' depression during COVID-19: A randomized controlled trial.

Internet Interventions April 21, 2026 Fei-Hsiu Hsiao, Chiao Lo, Wen-Hung Kuo et al.

Objectives: To test the effectiveness of mindful compassion integrated with body-mind-spirit (BMS) therapy delivered through a blended face-to-face and online approach for breast cancer patients. Methods: This randomized controlled trial (RCT) assigned 39 breast cancer patients to either a blended group (partial face-to-face and online sessions) or an online-only group. Both received eight...

DOI: 10.1016/j.invent.2026.100947 Full text Mindfulness Breast cancer Depressive symptoms Compassion +1

Neuroscientific Basis of Ketamine as an Analgesic and Emerging Role in the Management of Depression.

Current Pain and Headache Reports April 21, 2026 Navy C Coggins, Hanson A Chokr, Tricia A Meyer et al.

PURPOSE OF REVIEW: Ketamine was originally developed as a dissociative anesthetic and has remained a valuable agent in anesthesia related to its ability to preserve airway reflexes and relative hemodynamic stability. Over time, its clinical applications have expanded beyond procedural sedation to include roles in pain management and psychiatry. In pain medicine, the therapeutic rationale is...

DOI: 10.1007/s11916-026-01475-7 Full text Ketamine Treatment-resistant depression Central sensitization Multimodal analgesia +4

Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial.

Scientific Reports April 21, 2026 Rong Ding, Daojie Wang, Guoxin Wang et al.

Elderly colorectal cancer (CRC) patients face high risks of postoperative depression state, inadequately addressed by opioid-based analgesia. Esketamine, an NMDA receptor antagonist with rapid antidepressant effects, offers potential benefits but lacks evidence in this population. This double-blind RCT enrolled 99 elderly (≥ 65 years) CRC resection patients, randomized to three postoperative...

DOI: 10.1038/s41598-026-49287-4 Full text Esketamine Colorectal cancer Elderly Patient-controlled analgesia +1

The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes

Mental Wellness April 21, 2026 Mohsen Khosravi, Domenico de Berardis, Massimo Tusconi

This systematic review and meta-analysis synthesized data from 13 clinical trials (n=606) evaluating psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression. Despite early enthusiasm, the pooled standardized mean difference (-0.79, 95% confidence interval: -3.98 to 2.40, p=0.63) revealed no statistically significant overall antidepressant effect, with...

DOI: 10.4081/mw.2026.40 Major depressive disorder Treatment-resistant depression Meta-analysis Antidepressant +9

Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials

Open Access Indonesian Journal of Medical Reviews April 21, 2026 Siti Nashria Rusdhy, Andrian Fajar Kusumadewi, Carla Raymondalexas Marchira et al.

Psilocybin-assisted therapy shows promise for depression, though current evidence relies on Phase 2 trials with notable methodological limitations. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating psilocybin-assisted therapy for major or treatment-resistant depression up to February 2024. We evaluated depressive symptom severity using...

DOI: 10.37275/oaijmr.v6i2.883

REDUCTION IN SYMPTOMS OF POSTTRAUMATIC STRESS DISORDER AND DEPRESSION IN UKRAINIAN REFUGEES PRACTICING TRANSCENDENTAL MEDITATION

Clinical and Preventive Medicine April 20, 2026 Mykola Didukh, K. Freytag, Vitalii Lunov et al.

Introduction. Following the full-scale Russian invasion of Ukraine, there has been a substantial increase in the need for accessible, rapid-acting, and non-pharmacological approaches to alleviate symptoms of post-traumatic stress disorder and depression among Ukrainian refugees. One potentially useful intervention is the Transcendental Meditation program. Aim. To assess the effectiveness of the...

DOI: 10.31612/2616-4868.2.2026.07 Major depressive disorder Transcendental meditation Depression economics Intervention counseling +5

Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) on depression and anxiety in older adults: A systematic review and meta-analysis.

Journal of Behavior Therapy and Experimental Psychiatry April 20, 2026 Jieping Ding, Zafar Mehnaz Ali, Ateya Megahed Ibrahim et al.

Depression is a prevalent mental health issue among older adults, often exacerbated by chronic illness, social isolation, and age-related cognitive changes. Standard treatments (e.g., pharmacotherapy and cognitive behavioral therapy) may not always be effective, acceptable, or accessible for this population. Mindfulness-Based Cognitive Therapy (MBCT) integrates mindfulness practices with...

DOI: 10.1016/j.jbtep.2026.102105 Full text Anxiety Depression Meta-analysis Mindfulness-based cognitive therapy +2

Longitudinal Effects of Mindfulness Combined with Gratitude Touch on Anxiety, Depression, and Stress: A 12-Month Portable EEG-Based Study.

Brain Sciences April 18, 2026 Mădălina Sarca, Iuliana-Anamaria Trăilă, Teodora Anghel et al.

Background/Objectives: Mindfulness-based interventions are widely used to reduce psychological distress. Their long-term neurophysiological correlates remain insufficiently characterized. Using a portable Muse InteraXon® EEG device, this study aimed to evaluate (i) the extent to which a 12-month combined mindfulness and gratitude-based intervention reduces anxiety, depression, and perceived...

DOI: 10.3390/brainsci16040425 Full text Mindfulness Stress Longitudinal study Electroencephalography EEG +3

Psilocybin reshapes cortical inhibition through selective interneuron recruitment.

bioRxiv : the preprint server for biology April 17, 2026 Pasha A. Davoudian, Quan Jiang, Cory A. Knox et al. preprint

Psychedelics show therapeutic potential for treating psychiatric disorders. While studies have emphasized the roles of cortical pyramidal cells, GABAergic neurons also express serotonin receptors and are therefore likely targets of psychedelics. In this study, we determine the effect of psilocybin on the activity dynamics of major GABAergic cell types in the mouse medial frontal cortex....

DOI: 10.64898/2026.04.16.718963 Full text Depression Gabaergic neurons Disinhibition Microcircuit +2

Protocol and pilot results for a double-blind randomized placebo-controlled trial of ketamine under propofol sedation for chronic pain and depression.

Pain Management April 16, 2026 Theresa R. Lii, Pilleriin Sikka, Ben Deverett et al.

INTRODUCTION Ketamine shows promise for treatment-refractory chronic pain and depression, but randomized trials risk unblinding from ketamine's acute dissociative effects. Propofol sedation may mitigate this, though it has not been prospectively tested as a masking strategy outside of surgical contexts. METHODS This protocol describes a single-center, randomized, double-blind,...

DOI: 10.1080/17581869.2026.2658080 Full text

Innovative Approaches to Depression Therapy: The Antidepressant Efficacy and Mechanisms of General Anesthetics.

Current Neuropharmacology April 16, 2026 Xiangying Wei, Shan Xu, Zhaoqiong Zhu

Depression represents a critical global health burden, ranking as the second leading cause of disability worldwide. Although drug therapies remain an important cornerstone in treating depression, we must acknowledge their significant shortcomings: they often take too long to work, cause difficult side effects, and fail to prevent relapse. Critically, while current drugs target specific...

DOI: 10.2174/011570159x458197260226055817 Full text Depression Anesthetic therapeutics. General anesthetics

Comparison of average time-to-relapse following ECT versus ketamine - A systematic review.

Journal of Psychopharmacology April 16, 2026 Minna Chang, Allan H. Young, Mario F Juruena

Previous systematic reviews and meta-analyses have reported impressive antidepressant effects of ketamine in treatment-resistant depression (TRD). While ketamine has been compared with electroconvulsive therapy (ECT), the gold standard treatment, the extent and durability of its antidepressant effects over longer periods remain unclear. To our knowledge, this is the first systematic review...

DOI: 10.1177/02698811261430502 Full text Ketamine Major depressive disorder Treatment-resistant depression Antidepressant duration +3

Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes.

Journal of Intensive Care Medicine April 16, 2026 Vrutti Patel, Saurabh Sujanyal, Lekhya Raavi et al.

BackgroundKetamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU...

DOI: 10.1177/08850666261438474 Full text Depression Ketamine Hemodynamic stability Intensive care unit

A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?

Journal of Affective Disorders April 15, 2026 Gia Han Le, Sabrina Wong, Danica E. Johnson et al. 4 citations

Ketamine and esketamine exhibit rapid antidepressant effects in persons with treatment-resistant depression (TRD) and bipolar depression (TRBD). However, the synaptic mechanisms governing dose, frequency, and durability of response remain unclear. This review aims to evaluate the dosing parameters, including minimum dose and optimal dosing intervals, that reliably induce or maintain long-term...

DOI: 10.1016/j.jad.2025.121081 Full text Depressive disorder Ketamine Drug administration schedule Long-term potentiation +2

Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation.

Journal of Affective Disorders April 15, 2026 Jen-Ping Chen, Chih-Wei Hsu, Yi-Ting Chen et al.

Repetitive transcranial magnetic stimulation (rTMS) and esketamine are FDA-approved treatments for treatment-resistant depression (TRD), yet head-to-head comparative effectiveness data remain limited. Our study compared the effectiveness and safety profiles of rTMS versus esketamine in adults with TRD. This cohort study used target trial emulation with 1:1 propensity score matching on 50...

DOI: 10.1016/j.jad.2025.121132 Full text Esketamine Treatment-resistant depression Target trial emulation

Filtering the noise: a cerebellar-centered framework for understanding and treating mental illness -a paradigm shift in psychiatry

Frontiers in Psychiatry April 13, 2026 Craig F. Ferris

For the past half-century, psychiatric drug development has largely focused on tweaking neurotransmitter receptors and chemical pathways. Yet despite billions of dollars invested and major advances in neuroscience, truly innovative treatments for mental illness remain scarce. Disorders like depression, schizophrenia, and post-traumatic stress disorder (PTSD) continue to be managed with drugs...

DOI: 10.3389/fpsyt.2026.1772265 Neuroplasticity Major depressive disorder Mental illness Schizophrenia object-oriented programming +8

Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.

Translational Psychiatry April 10, 2026 Ting-Hui Liu, Hong-Shiang Shen, Jheng-Yan Wu et al. 1 citation

This study aimed to evaluate the long-term effectiveness and safety of esketamine in adults with Major depressive disorder (MDD), focusing on suicide-related events, all-cause mortality, and major adverse cardiovascular events (MACEs). This target-trial simulation used the TriNetX Global Collaborative Network. Adults (≥ 18 years) with MDD who received either esketamine or a conventional...

DOI: 10.1038/s41398-026-04032-3 Full text Ketamine Major depressive disorder Humans Antidepressive agents +5

Studies